Mardi 24 novembre 2020 - 02:10 | A ne pas manquer : Le 10 Décembre 2020 - Réunion de la Banque centrale européenne

Elsevier mdl et spotfire forment un partenariat strat?gique ?largi ; l'application spotfire visual analytics supportera la nouvelle plate-forme mdl isentris ; les soci?t?s ...

Presse économique / Santé / Médical

SAN LEANDRO, Californie, et SOMERVILLE, Massachusetts -- (BUSINESS WIRE) -- June 22, 2005 -- Elsevier MDL et Spotfire, Inc., ont formé un partenariat stratégique visant à instaurer une relation étroite entre la plate-forme technologique nouvelle génération MDL® Isentris® et l'application Spotfire® DecisionSite® pour la recherche et le développement de nouveaux médicaments.

Elsevier MDL and Spotfire Form Expanded Strategic Partnership; Spotfire Visual Analytics to Support New MDL Isentris Platform, Companies Exploring Further Development

Business Editors/Health/Medical Writers

SAN LEANDRO, Calif. and SOMERVILLE, Mass.--(BUSINESS WIRE)--June 22, 2005--Elsevier MDL and Spotfire, Inc. have formed a strategic partnership to create a strong link between the new-generation MDL(R) Isentris(R) technology platform and the Spotfire(R) DecisionSite(R) for Lead Discovery application..

The collaboration will enable customers in biopharmaceutical R&D to achieve new levels of productivity and integration, offering researchers improved compatibility between the industry-leading systems for data integration and application building and for visual analytics

As the first steps in a series of projects to link the products, Spotfire plans to deliver support for Isentris products before the end of 2005, and Elsevier MDL plans to develop value-added software extensions to the widely deployed and highly configurable DecisionSite platform, providing even stronger interoperability with MDL Isentris

"It's exciting when two companies with vital and complementary product offerings can partner to make their products work even better for customers -- especially when supporting important biopharmaceutical research," said Elsevier MDL CEO Lars Barfod.

"This cooperation marks a new stage in the long relationship between Elsevier MDL and Spotfire and strengthens the value of both companies' products to mutual customers."

"Together, Spotfire and Elsevier MDL can offer research organizations more comprehensive discovery solutions," said Spotfire CEO Christopher Ahlberg.

"In the short term, customers will see out-of-the-box compatibility between MDL Isentris and DecisionSite for Lead Discovery.

Meanwhile, we'll explore further developments that leverage these frameworks to improve scientists' productivity from target identification to drug safety."

The agreement includes strategic membership for Spotfire in the MDL(R) Isentris Alliance program (a community of companies joining forces to improve the value of offerings from different vendors by utilizing an open technology framework) and reciprocal membership for Elsevier MDL in the Spotfire Alliance Partnership Program, as well as a mutual exchange of developer licenses and training to facilitate collaborative development

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making.

Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products.

For more information, visit

Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

For more information, visit

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider


Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

For more information, visit

About Spotfire, Inc

Spotfire, Inc. provides interactive, visual data analytics applications and services that empower enterprises and their end-users to improve operational performance and gain an information advantage over the competition.

Over 25,000 users in close to 1,000 organizations around the world use Spotfire DecisionSite to drive confident decision-making by quickly and easily spotting trends, outliers and unanticipated relationships in critical business data

The company maintains U.S. headquarters in Somerville, Mass., and European headquarters in Goteborg, Sweden.

Additional information can be found at:

About MDL Isentris

MDL Isentris is the first complete, out-of-the-box, n-tier informatics architecture supporting enterprise-wide business process, data and application integration for the life sciences.

Isentris streamlines the storage, integration and retrieval of a broad range of chemistry and biology data, enabling scientists to access the right information at the right time, in the right context and format

About Spotfire DecisionSite

The world's largest pharmaceutical companies and most successful biotechs use Spotfire DecisionSite interactive visual analytic applications across a spectrum of research and development processes, to help their analysts make informed decisions that reduce time to market, reduce risk and ultimately improve the safety and effectiveness of new drugs.

DecisionSite visual analytics helps pharmaceutical and biotech companies quickly spot critical trends, outliers and unanticipated relationships in data

MDL and Isentris are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States and/or other countries.

All rights reserved.

Spotfire and DecisionSite are registered trademarks of Spotfire, Inc. Other company or product names may be the trademarks of their respective owners


Elsevier MDL Erik Miller, 510-357-2222 ext. 1371

email: or Spotfire, Inc

Amy Groden, 617-702-1710




SOURCE: Elsevier MDL

ETAM DEVELOPPEMENT : Note d'information

Ce contenu est diffusé par Hugin, il n`a qu`une portée informative et pédagogique.Les informations et données financières ainsi que les analyses diffusées par Hugin n`ont aucune valeur contractuelle et ne constituent en aucun cas une aide à la décision, une offre de vente ou une sollicitation d`achat de valeurs mobilières ou d`instruments financiers.

La responsabilité de et/ou de ses dirigeants et salariés ne peut être retenue directement ou indirectement suite à l`utilisation des informations et analyses par les lecteurs et sur la pertinence des informations diffusées.

Il est recommandé à toute personne non avertie de consulter un conseiller professionnel avant tout investissement, car le trading peut vous exposer à des pertes supérieures aux dépôts chez votre broker.

Tout investisseur doit se faire son propre jugement avant d`investir dans un produit financier afin qu`il soit adapté à sa situation financière, fiscale et légale

Vous aimerez aussi